Research progress of the key targets of autophagy and related drugs in mammalian cells

doi:10.12092/j.issn.1009-2501.2018.02.017

Abstract

Abstract:

Autophagy is a catabolic process for the degradation and recycling of macromolecules and organelles, which is activated during stress conditions. It plays an important role in maintain a homeostasis in the cell, and is closely related to many diseases, especially the development of tumor, which makes researchers pay more attention on control autophagy as a target of new drug development and clinical application. However, the mechanism of autophagy process is very complicated. This article reviews the research progress of crucial targets mTOR, ULK, Beclin 1, Atg12 connection system, LC3 lipid connection system and p62/SQSM1, which are involved in autophagy signaling pathways and its related drugs.

Key words: autophagy, target, signaling pathway, drug development

CLC Number:

R966

WANG Xin, CHEN Baoqiang, LI Hongyu. Research progress of the key targets of autophagy and related drugs in mammalian cells[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 205-210.

References

［1］Kundu M, Thompson CB. Autophagy: basic principles and relevance to disease［J］. Annu Rev Pathol, 2008, 3: 427-455.
［2］Murrow L, Debnath J. Autophagy as a stress-response and quality-control mechanism: implications for cell injury and human disease［J］. Annu Rev Pathol, 2013, 8:105-137.
［3］Mizushima N, Levine B, Cuervo AM, et al. Autophagy fights disease through cellular self-digestion ［J］. Nature, 2008,451(7182): 1069-1075.
［4］Yang Q, Guan KL. Expanding mTOR signaling［J］. Cell Res, 2007,17(8): 666-681.
［5］李乐兴,戴汉川.细胞自噬调控的分子机制研究进展［J］.中国细胞生物学学报,2015,37(2):263-270.
［6］Kim YC, Guan KL. mTOR: a pharmacologic target for autophagy regulation［J］. J Clin Invest, 2015,125(1): 25-32.
［7］Wu YT, Tan HL, Shui G, et al. Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class I and III phosphoinositide 3-kinase［J］. J Biol Chem, 2010, 285(14): 10850-10861.
［8］F OF, Rusten TE, Stenmark H. Phosphoinositide 3-kinases as accelerators and brakes of autophagy［J］. FEBS J, 2013, 280(24): 6322-6337.
［9］Shanware NP, Bray K, Abraham RT. The PI3K, metabolic, and autophagy networks: interactive partners in cellular health and disease［J］. Annu Rev Pharmacol Toxicol, 2013, 53: 89-106.
［10］Dinner S, Platanias LC. Targeting the mTOR Pathway in Leukemia［J］. J Cell Biochem, 2016, 117(8): 1745-1752.
［11］Li X, Wu C, Chen N, et al. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma［J］. Oncotarget, 2016, 7(22): 33440-33450.
［12］Guerrero-Zotano A, Mayer IA, Arteaga CL. PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment［J］. Cancer Metastasis Rev, 2016,35(4):515-524.
［13］Chen R, Duan J, Li L, et al. mTOR promotes pituitary tumor development through activation of PTTG1［J］. Oncogene, 2017, 36(7):979-988.
［14］Rodon J, Brana I, Siu LL, et al. Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors［J］. Invest New Drugs, 2014,32(4): 670-681.
［15］Ihle NT, Williams R, Chow S, et al. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling［J］. Mol Cancer Ther, 2004,3(7):763-772.
［16］Civallero M, Cosenza M, Pozzi S, et al. Activity of BKM120 and BEZ235 against lymphoma cells［J］. Biomed Res Int, 2015: 870918-870930.
［17］Pal SK,Reckamp K,Yu H,et al.Akt inhibitors in clinical development for the treatment of cancer［J］.Expert Opin Investig Drugs,2010,19(11):1355-1366.
［18］Zhao YY, Tian Y, Zhang J, et al. Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo［J］. Drug Des Devel Ther, 2014, 8: 1827-1837.
［19］Cani A, Simioni C, Martelli AM, et al. Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia［J］. Oncotarget, 2015, 6(9): 6597-6610.
［20］Song X, Kim SY, Zhang L, et al. Role of AMP-activated protein kinase in cross-talk between apoptosis and autophagy in human colon cancer［J］. Cell Death Dis, 2014, 5: e1504.
［21］Feldman ME, Shokat KM. New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs)［J］. Curr Top Microbiol Immunol, 2010, 347: 241-262.
［22］Suangtamai T, Tanyong DI. Diallyl disulfide induces apoptosis and autophagy via mTOR pathway in myeloid leukemic cell line［J］. Tumour Biol, 2016, 37(8):10993-10999.
［23］Hu M, Huang H, Zhao R, et al. AZD8055 induces cell death associated with autophagy and activation of AMPK in hepatocellular carcinoma［J］. Oncol Rep, 2014, 31(2):649-656.
［24］Yongxi T, Haijun H, Jiaping Z, et al. Autophagy inhibition sensitizes KU-0063794-mediated anti-HepG2 hepatocellular carcinoma cell activity in vitro and in vivo［J］. Biochem Biophys Res Commun, 2015, 465(3): 494-500.
［25］Rodrik-Outmezguine VS, Okaniwa M, Yao Z, et al. Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor［J］. Nature, 2016, 534(7606): 272-276.
［26］Mazan-Mamczarz K, Peroutka RJ, Steinhardt JJ, et al. Distinct inhibitory effects on mTOR signaling by ethanol and INK128 in diffuse large B-cell lymphoma［J］. Cell Commun Signal, 2015, 13: 1-15.
［27］Ghosh J,Kapur R.Role of mTORC1-S6K1 signaling pathway in regulation of hematopoietic stem cell and acute myeloid leukemia［J］.Exp Hematol,2017,50:13-21.
［28］Chan EY, Longatti A, McKnight NC, et al. Kinase-inactivated ULK proteins inhibit autophagy via their conserved C-terminal domains using an Atg13-independent mechanism［J］. Mol Cell Biol, 2009, 29(1):157-171.
［29］Hara T, Takamura A, Kishi C, et al. FIP200, a ULK-interacting protein, is required for autophagosome formation in mammalian cells［J］. J Cell Biol, 2008, 181(3):497-510.
［30］Nishimura T, Kaizuka T, Cadwell K, et al. FIP200 regulates targeting of Atg16L1 to the isolation membrane［J］. EMBO Rep, 2013, 14(3): 284-291.
［31］付婉, 董笛, 赵颖. 自噬的相关分子机制［J］. 中国生物化学与分子生物学报, 2017, 33(5): 448-455.
［32］Jung CH,Jun CB,Ro SH,et al.ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery［J］.Mol Biol Cell,2009,20(7):1992-2003.
［33］Kim J, Kundu M, Viollet B, et al. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1［J］. Nat Cell Biol, 2011,13(2): 132-141.
［34］ Pasquier B, Autophagy inhibitors［J］. Cell Mol Life Sci, 2016, 73(5): 985-1001.
［35］Petherick KJ,Conway OJ,Mpamhanga C,et al.Pharmacological inhibition of ULK1 kinase blocks mammalian target of rapamycin(mTOR)-dependent autophagy［J］.J Biol Chem,2015,290(18):11376-11383.
［36］Egan DF, Chun MG, Vamos M, et al. Small molecule inhibition of the autophagy kinase ULK1 and identification of ULK1 substrates ［J］. Mol Cell, 2015, 59(2): 285-297.
［37］Mei Y,Glover K,Su M,et al.Conformational flexibility of BECN1:Essential to its key role in autophagy and beyond［J］.Protein Sci,2016,25(10):1767-1785.
［38］Fu LL, Cheng Y, Liu B. Beclin-1: autophagic regulator and therapeutic target in cancer［J］. Int J Biochem Cell Biol, 2013, 45(5): 921-924.
［39］Sinha S, Levine B. The autophagy effector Beclin 1: a novel BH3-only protein［J］. Oncogene, 2008, 27( Suppl 1): S137-148.
［40］Sun Q,Fan W,Chen K,et al.Identification of Barkor as a mammalian autophagy-specific factor for Beclin 1 and class III phosphatidylinositol 3-kinase［J］.Proc Natl Acad Sci USA,2008,105(49):19211-19216.
［41］Liang C, Feng P, Ku B, et al. Autophagic and tumour suppressor activity of a novel Beclin1-binding protein UVRAG［J］. Nat Cell Biol, 2006, 8(7): 688-699.
［42］Cao Y, Klionsky DJ. Physiological functions of Atg6/Beclin 1: a unique autophagy-related protein［J］. Cell Res, 2007,17(10): 839-849.
［43］Wirawan E, Lippens S, Vanden Berghe T, et al. Beclin1: a role in membrane dynamics and beyond［J］. Autophagy, 2012, 8(1): 6-17.
［44］Sun Q, Fang W, Zhong Q. Regulation of Beclin 1 in autophagy［J］. Autophagy, 2009,5(5): 713-716.
［45］Liang C, Feng P, Ku B, et al. UVRAG: A new player in autophagy and tumor cell growth. Autophagy, 2014, 3(1): 69-71.
［46］Liang C, Lee JS, Inn KS, et al. Beclin1-binding UVRAG targets the class C Vps complex to coordinate autophagosome maturation and endocytic trafficking［J］. Nat Cell Biol, 2008, 10(7): 776-787.
［47］Lindqvist LM, Heinlein M, Huang DC, et al. Prosurvival Bcl-2 family members affect autophagy only indirectly, by inhibiting Bax and Bak［J］. Proc Natl Acad Sci U S A, 2014, 111(23): 8512-8517.
［48］ Jung YY,Lee YK,Koo JS.The potential of Beclin 1 as a therapeutic target for the treatment of breast cancer［J］.Expert Opin Ther Targets,2016,20(2):167-178.
［49］Malik SA, Orhon I, Morselli E, et al. BH3 mimetics activate multiple pro-autophagic pathways［J］. Oncogene, 2011,30(37): 3918-3929.
［50］Hoyer-Hansen M, Bastholm L, Mathiasen IS, et al. Vitamin D analog EB1089 triggers dramatic lysosomal changes and Beclin 1-mediated autophagic cell death［J］. Cell Death Differ, 2005, 12(10): 1297-1309.
［51］Lian J, Wu X, He F, et al. A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2-Beclin1 interaction at endoplasmic reticulum［J］. Cell Death and Differentiation, 2010,18(1): 60-71.
［52］Tang B, Dong X, Wei Z, et al. Enhanced autophagy by everolimus contributes to the antirestenotic mechanisms in vascular smooth muscle cells［J］. J Vasc Res, 2014, 51(4):259-268.
［53］Kim DE, Kim Y, Cho DH, et al. Raloxifene induces autophagy-dependent cell death in breast cancer cells via the activation of AMP-activated protein kinase［J］. Mol Cells, 2015, 38(2): 138-144.
［54］Shao S, Li S, Qin Y, et al. Spautin-1, a novel autophagy inhibitor, enhances imatinib-induced apoptosis in chronic myeloid leukemia［J］. Int J Oncol, 2014,44(5):1661-1668.
［55］Vicencio JM, Ortiz C, Criollo A, et al. The inositol 1,4,5-trisphosphate receptor regulates autophagy through its interaction with Beclin 1［J］. Cell Death Differ, 2009, 16(7):1006-1017.
［56］Tanida I, Autophagy basics［J］. Microbiol Immunol, 2011, 55(1): 1-11.
［57］Shibutani ST, Yoshimori T. A current perspective of autophagosome biogenesis［J］. Cell Res, 2014, 24(1):58-68.
［58］Kabeya Y, Mizushima N, Ueno T, et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing［J］. Embo j, 2000, 19(21): 5720-5728.
［59］Fujita N, Itoh T, Omori H, et al. The Atg16L complex specifies the site of LC3 lipidation for membrane biogenesis in autophagy［J］. Mol Biol Cell, 2008, 19(5): 2092-2100.
［60］Sakoh-Nakatogawa M, Matoba K, Asai E, et al. Atg12-Atg5 conjugate enhances E2 activity of Atg3 by rearranging its catalytic site［J］. Nat Struct Mol Biol, 2013, 20(4):433-439.
［61］Dooley HC, Razi M, Polson HE, et al. WIPI2 links LC3 conjugation with PI3P, autophagosome formation, and pathogen clearance by recruiting Atg12-5-16L1［J］. Mol Cell, 2014, 55(2):238-252.
［62］Martinez J, Cunha LD, Park S, et al. Noncanonical autophagy inhibits the autoinflammatory, lupus-like response to dying cells［J］. Nature, 2016, 533(7601): 115-119.
［63］Lin X, Li S, Zhao Y, et al. Interaction domains of p62: a bridge between p62 and selective autophagy［J］. DNA Cell Biol, 2013,32(5): 220-227.
［64］Lippai M, Low P.The role of the selective adaptor p62 and ubiquitin-like proteins in autophagy［J］. Biomed Res Int, 2014, 2014: 832704-832715.
［65］Pankiv S, Clausen TH, Lamark T, et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy［J］. J Biol Chem, 2007, 282(33): 24131-24145.
［66］Duran A, Amanchy R, Linares JF, et al. p62 is a key regulator of nutrient sensing in the mTORC1 pathway［J］. Mol Cell, 2011, 44(1): 134-146.
［67］Linares JF, Duran A, Reina-Campos M, et al. Amino Acid Activation of mTORC1 by a PB1-Domain-Driven Kinase Complex Cascade［J］. Cell Rep, 2015, 12(8): 1339-1352.

[1]	WANG Jie, LI Long, CHEN Feng, LIU Shengfei. Research progress of nuclear factor erythroid 2-related factor 2 in pulmonary fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1067-1072.
[2]	ZHANG Huyunlong, ZHU Xiuzhi, JIN Xi, SHAO Zhimin. Mechanisms of endocrine-resistance and therapeutic breakthroughs in hormone receptor-positive, HER2-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 854-865.
[3]	LUO Shiping, ZHANG Jie, YU Yushuai, SONG Chuangui. Advances in targeted therapy for HER2-positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 876-886.
[4]	XIANG Yimei, ZHANG Ningning, HUANG Yuxin, ZENG Xiaohua. Research progress of biomarkers related to the efficacy of HER2 positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 887-897.
[5]	WANG Anjing, WANG Yaya, LIANG Xuan, YAN Yajie, SU Jing, LI Caidong. Research progress on mechanisms and therapeutic drugs of peroxisome proliferator-activated receptor in treatment of cholestatic liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 796-808.
[6]	QIN Wenxiu, XU Junfeng, YANG Ting, WANG Pingfei. Research progress on signaling pathway of tanshinoneIIA in treatment of nerve injury after ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 705-713.
[7]	CHEN Manxin, ZHANG Bingyu, DAI Min. Clinical efficacy of intracoronally targeted recombinant human urokinase combined with percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI) with high thrombus burden [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 544-549.
[8]	FENG Zhuangzhuang, SONG Ruiping, DOU Pengcheng, CHEN Xinyi, ZUO Jiaojiao, SHU Jin. Effect of Zhiwei Fuwei Pills on autophagy in gastric antrum tissue of rats with precancerous lesions of gastric cancer based on mTOR/Beclin1/LC3 signaling axis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 361-370.
[9]	HOU Ruiying, GUO Lige, JIAO Weijie, DU Lei, WU Guiyue, ZHAO Xu. Effects of Xiaokeshu recipe on levels of serum inflammatory factors in type2 diabetic rats and its mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 377-382.
[10]	LI Ruoning, GUO Zhanli, WANG Yuan, SUN Jianjun. Platelet-endothelial aggregation receptor 1 and its mediated signalling pathway Advances in the study of the role of platelets and endothelial cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 438-444.
[11]	NING Sisi, ZHAO Yuhong, YAN Lei, TANG Minna, ZHANG Ningzhi, ZHANG Yongqiao, CUI Zhaoqiang. Controversies over the targets of controlling blood pressure in hyper- tensive patients with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 463-467.
[12]	MA Guangli, ZHANG Jing. Application of quantitative pharmacology in vaccine research and de-velopment: overview and prospect [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 315-322.
[13]	BAI Jia, YANG Hong, LI Lingling, ZHANG Yangyang, YANG Ying, LV Haihong. Study on the effect of vitamin D on diabetic neuropathy through mitochondrial/autophagy pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 214-219.
[14]	WANG Jie, LI Long, CHEN Feng, LIU Shengfei. Research progress of metformin in the pathogenesis of pulmonary fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 235-240.
[15]	ZHU Ruifang, GUO Dongkai, ZHI Hui, JIANG Yiguo, ZHANG Yueling, QIAN Xiaoping, JI Shiliang. Exploring the mechanism of elemene synergistic bortezomib against multiple myeloma by ROS-NF-κB-p38MAPK pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1219-1226.